Clene stock analysis
Clene (84C0) Stock Price & Analysis
84C0 Stock Chart & Stats
- Day’s Range
- EUR 3.04 - EUR 3.06
- 52-Week Range
- EUR 2.68 - EUR 9.35
- Previous Close
- EUR 2.86
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 45.93M
- Enterprise Value
- EUR 72.57M
- Total Cash (Recent Filing)
- EUR 9.89M
- Total Debt (Recent Filing)
- EUR 22.60M
- Price to Earnings (P/E)
- ―
- Beta
- 0.75
- Next Earnings
- Mar 29, 2027 (Est.)
- EPS Estimate
- -0.43
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
ALS Regulatory Progress
The ALS NDA submission is a major development milestone that moves CNM-Au8 from clinical development toward potential regulatory review and commercialization. Continued preparation for a confirmatory Phase 3 study also supports the candidate’s strategic importance and development pathway.
Non-Dilutive Development Funding
The NIH subaward provides externally funded support for CNM-Au8 access and development activities, reducing the amount of corporate capital required for this program. Multi-year grant backing also reinforces institutional support for the ALS therapeutic effort.
Insider Capital Support
The insider-led financing supplies near-term liquidity for regulatory dialogue, filings, expanded access, potential commercialization and manufacturing preparation. Participation by company insiders also demonstrates continued financial support for advancing CNM-Au8.
Bears Say
Persistent Unprofitability
The company remains deeply unprofitable, with losses far exceeding its small revenue base and negative TTM gross profit. Such stressed economics make a near-term transition to self-funded operations unlikely and leave future value dependent on clinical and regulatory success.
Ongoing Cash Burn
Cash usage remains substantial even after moderating from earlier years, while free cash flow closely tracks net loss and confirms that losses translate into real funding needs. Continued development therefore requires additional financing or other external capital sources.
Weak Capital Structure
Negative equity and a materially smaller asset base indicate limited balance-sheet flexibility, while sizable debt remains outstanding. This capital structure can constrain investment capacity and increase reliance on future financing as clinical and regulatory spending continues.
Clene News
84C0 FAQ
What was Clene’s price range in the past 12 months?
What is Clene’s market cap?
When is Clene’s upcoming earnings report date?
How were Clene’s earnings last quarter?
Is Clene overvalued?
Does Clene pay dividends?
What is Clene’s EPS estimate?
How many shares outstanding does Clene have?
What happened to Clene’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Clene?
What is the TipRanks Smart Score and how is it calculated?
Clene Stock Smart Score
Company Description
Clene
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
- Sector
- Consumerdefensive
- Industry
- Biotechnology
- CEO
- Robert Etherington
- Employees
- 78
- Website
- clene.com
- Address
- 6550 South Millrock Drive, Salt Lake City, UT, 84121, US
Clene (84C0) Earnings & Revenues
84C0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |










